Brind.

Precision BioSciences and Incepta Pharmaceuticals were noted as belonging to a specified industry in August 2025.

2 reports, 2 independent Updated Sat 00:00

No new developments lately

Reports: 2
Developments: 2
Repetition: 0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Precision BioSciences and Incepta Pharmaceuticals were noted as belonging to a specified industry in August 2025.

Who's involved

What this event is mainly about

Precision BioSciences Incepta Pharmaceuticals

How it developed

Newest first. Tap a step to see who reported it.

Sat 00:00MarketBeat summarizes recommendations for Precision BioSciences, which operates in the US market.1 source
- themarketsdaily.com
Aug 7Precision BioSciences and Incepta Pharmaceuticals were classified within a specific industry sector.1 source
- Zacks

Keep exploring

The entities involved

Precision BioSciences
American gene editing company

Nothing else this week.
Incepta Pharmaceuticals
incepta
- Tilray Brands, Inc.'s stock change lagged the S&P 500 gain on August 28, 2025, while the company holds a Zacks Rank of #3.Sun 03:24

Coverage

Newest first; wire copies grouped

Sat 00:00themarketsdaily.com
Aug 7ZacksPrecision BioSciences (DTIL) Reports Q2 Loss, Lags Revenue Estimates Precision BioSciences (DTIL) came out with a quarterly loss of $2.13 per share versus the Zacks Consensus Estimate of a loss of $0